Phase 0 and phase III transport in various organs: Combined concept of phases in xenobiotic transport and metabolism

Drug Metabolism Reviews

Volumn 46, Issue 3, 2014, Pages 261-282

  Döring, Barbara ^a   Petzinger, Ernst ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

ABC transporters; BCRP; Blood tissue barrier; Drug transport; MDR1; Metabolism transport interplay; MRP2; Phase0

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; DRUG CARRIER; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN; ORGANIC CATION TRANSPORTER; XENOBIOTIC AGENT; CARRIER PROTEIN;

BIOAVAILABILITY; CLASSIFICATION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; HUMAN; NONHUMAN; REVIEW; TISSUE SPECIFICITY; ANIMAL; DRUG INACTIVATION; LIVER; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; DRUG CARRIERS; HUMANS; INACTIVATION, METABOLIC; LIVER; MEMBRANE TRANSPORT PROTEINS; XENOBIOTICS;

EID: 84905496565     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2014.882353     Document Type: Review

References (320)

1. Agarwal S, Hartz AM, Elmquist WF, Bauer B. (2011). Breast cancer resistance protein and P-glycoprotein in brain cancer: Two gatekeepers team up. Curr Pharm Des 17:2793-2802.
2. Albrecht C, Viturro E. (2007). The ABCA subfamily-gene and protein structures, functions and associated hereditary diseases. Pflugers Arch 453:581-589.
3. Allikmets R, Schriml LM, Hutchinson A, et al. (1998). A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58: 5337-5339.
4. Amidon GL, Lennernas H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
5. Aouida M, Poulin R, Ramotar D. (2010). The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem 285:6275-6284.
6. Ballatori N, Christian WV, Lee JY, et al. (2005). OSTalpha-OSTbeta: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 42:1270-1279.
7. Ballatori N, Fang F, Christian WV, et al. (2008). Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver. Am J Physiol Gastrointest Liver Physiol 295:G179-G186.
8. Ballatori N, Christian WV, Wheeler SG, Hammond CL. (2013). The heteromeric organic solute transporter, OSTalpha-OSTbeta/SLC51: A transporter for steroid-derived molecules. Mol Aspects Med 34: 683-692.
9. Bao Y, Pucci ML, Chan BS, et al. (2002). Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids. Am J Physiol Renal Physiol 282:F1103-F1110.
10. Bavro VN, Pietras Z, Furnham N, et al. (2008). Assembly and channel opening in a bacterial drug efflux machine. Mol Cell 30: 114-121.
11. Belinsky MG, Kruh GD. (1999). MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver. Br J Cancer 80:1342-1349.
12. Benet LZ, Cummins CL, Wu CY (2004). Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277:3-9.
13. Benet LZ. (2009). The drug transporter-metabolism alliance: Uncovering and defining the interplay. Mol Pharm 6:1631-1643.
14. Benet LZ, Larregieu CA. (2010). The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted. Clin Pharmacol Ther 88:405-407.
15. Benet LZ, Broccatelli F, Oprea TI. (2011). BDDCS applied to over 900 drugs. AAPS J 13:519-547.
16. Binkhathlan Z, Lavasanifar A. (2013). P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives. Curr Cancer Drug Targets 13: 326-346.
17. Bleasby K, Castle JC, Roberts CJ, et al. (2006). Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition. Xenobiotica 36: 963-988.
18. Borst P, Oude Elferink RP. (2002). Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592.
19. Brandsch M, Knutter I, Bosse-Doenecke E. (2008). Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol 60:543-585.
20. Brandsch M. (2009). Transport of drugs by proton-coupled peptide transporters: Pearls and pitfalls. Expert Opin Drug Metab Toxicol 5: 887-905.
21. Breier A, Gibalova L, Seres M, et al. (2013). New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem 13: 159-170.
22. Broccatelli F, Mannhold R, Moriconi A, et al. (2012). QSAR modeling and data mining link torsades de pointes risk to the interplay of extent of metabolism, active transport, and hERG liability. Mol Pharm 9: 2290-2301.
23. Brodie BB, Hogben CA. (1957). Some physico-chemical factors in drug action. J Pharm Pharmacol 9:345-380.
24. Brodie BB. (1964). Physico-chemical factors in drug absorption. In: Binns TB, ed. Absorption and Distribution of Drugs. Edingburgh: Livingstone, 16-48.
25. Burckhardt BC, Burckhardt G. (2003). Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol 146:95-158.
26. Burckhardt G, Burckhardt BC. (2011). In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol 201:29-104.
27. Burckhardt G. (2012). Drug transport by Organic Anion Transporters (OATs). Pharmacol Ther 136:106-130.
28. Büchler MJ, Brom M, Kartenbeck J, et al. (1996). cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilir-ubinemic mutant rats. J Biol Chem 271:15091-15098.
29. Cano-Soldado P, Pastor-Anglada M. (2012). Transporters that translocate nucleosides and structural similar drugs: Structural requirements for substrate recognition. Med Res Rev 32:428-457.
30. Cascorbi I. (2011). P-glycoprotein: Tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 201:261-283.
31. Chai J, He Y, Cai SY, et al. (2012). Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway. Hepatology 55: 1485-1494.
32. Chen CJ, Chin JE, Ueda K, et al. (1986). Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381-389.
33. Chen ML, Amidon GL, Benet LZ, et al. (2011). The BCS, BDDCS, and regulatory guidances. Pharm Res 28:1774-1778.
34. Choi MK, Song IS. (2008). Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 23:243-253.
35. Chu XY, Strauss JR, Mariano MA, et al. (2006). Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). J Pharmacol Exp Ther 317:579-589.
36. Ciarimboli G. (2008). Organic cation transporters. Xenobiotica 38: 936-971.
37. Cole SP, Bhardwaj G, Gerlach JH, et al. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654.
38. Congiu M, Mashford ML, Slavin JL, Desmond PV. (2009). Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease. J Gastroenterol Hepatol 24:1038-1044.
39. Cordon-Cardo C, O'Brien JP, Casals D, et al. (1989). Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86: 695-698.
40. Cordon-Cardo C, O'Brien JP, Boccia J, et al. (1990). Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287.
41. Court MH, Duan SX, von Moltke LL, et al. (2001). Interindividual variability in acetaminophen glucuronidation by human liver microsomes: Identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299: 998-1006.
42. Crane RK, Krane SM. (1959). Studies on the mechanism of the intestinal active transport of sugars. Biochim Biophys Acta 31:397-401.
43. +-dependent transport in the intestine and other animal tissues. Fed Proc 24:1000-1006.
44. Crane RK. (1977). The gradient hypothesis and other models of carrier-mediated active transport. Rev Physiol Biochem Pharmacol 78: 99-159.
45. Cui Y, König J, Buchholz JK, et al. (1999). Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929-937.
46. Cummins CL, Wu CY, Benet LZ. (2002). Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 72:474-489.
47. Cummins CL, Salphati L, Reid MJ, Benet LZ. (2003). In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: Studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther 305:306-314.
48. + symporter. J Clin Invest 92:2215-2223.
49. Dauchy S, Dutheil F, Weaver RJ, et al. (2008). ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem 107:1518-1528.
50. Dean M, Hamon Y, Chimini G. (2001). The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42:1007-1017.
51. Declèves X, Jacob A, Yousif S, et al. (2011). Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Curr Drug Metab 12:732-741.
52. del Moral RG, Olmo A, Aguilar M, O'Valle F. (1998). P glycoprotein: A new mechanism to control drug-induced nephrotoxicity. Exp Nephrol 6:89-97.
53. Dietrich CG, de Waart DR, Ottenhoff R, et al. (2001). Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6- phenylimidazo[4, 5-b]pyridine in MRP2-deficient rats. Mol Pharmacol 59:974-980.
54. Donner MG, Keppler D. (2001). Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 34: 351-359.
55. Doran A, Obach RS, Smith BJ, et al. (2005). The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165-174.
56. Doyle LA, Yang W, Abruzzo LV, et al. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
57. Dreisbach AW, Lertora JJ. (2008). The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 4: 1065-1074.
58. Dürr D, Stieger B, Kullak-Ublick GA, et al. (2000). St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598-604.
59. Eechoute K, Sparreboom A, Burger H, et al. (2011). Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 17:406-415.
60. Eisenblätter T, Hüwel S, Galla HJ. (2003). Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res 971:221-231.
61. EMA. (June 2012). Guideline on the Investigation of Drug Interactions.
62. Engler JR, Frede A, Saunders VA, et al. (2010). Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 24:765-770.
63. Enomoto A, Wempe MF, Tsuchida H, et al. (2002). Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J Biol Chem 277:36262-36271.
64. Ernst E. (2002). St John's Wort supplements endanger the success of organ transplantation. Arch Surg 137:316-319.
65. Ernst R, Kueppers P, Stindt J, et al. (2010). Multidrug efflux pumps: Substrate selection in ATP-binding cassette multidrug efflux pumps-first come, first served? FEBS J 277:540-549.
66. Evers R, Kool M, van Deemter DL, et al. (1998). Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 101:1310-1319.
67. Fagiolino P, Vàzquez M, Eiraldi R, et al. (2011). Influence of efflux transporters on drug metabolism: theoretical approach for bioavailability and clearance prediction. Clin Pharmacokinet 50: 75-80.
68. Fahrmayr C, König J, Auge D, et al. (2013). Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4- UGT1A1-MRP2 quadruple-transfected cell line. Br J Pharmacol 169:21-33.
69. Fan Y, Rodriguez-Proteau R. (2008). Ketoconazole and the modulation of multidrug resistance-mediated transport in Caco-2 and MDCKII-MDR1 drug transport models. Xenobiotica 38:107-129.
70. FDA. (February 2012). Draft guidance for industry: Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations.
71. Fehrenbach T, Cui Y, Faulstich H, Keppler D. (2003). Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol 368: 415-420.
72. Fetsch PA, Abati A, Litman T, et al. (2006). Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett 235:84-92.
73. Franke RM, Gardner ER, Sparreboom A. (2010). Pharmacogenetics of drug transporters. Curr Pharm Des 16:220-230.
74. Fromm MF. (2004). Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25:423-429.
75. Furman WL, Navid F, Daw NC, et al. (2009). Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 27:4599-4604.
76. Ganapathy V, Leibach FH. (1983). Role of pH gradient and membrane potential in dipeptide transport in intestinal and renal brush-border membrane vesicles from the rabbit. Studies with L-carnosine and glycyl-L-proline. J Biol Chem 258:14189-14192.
77. Gavrilova O, Geyer J, Petzinger E. (2007). In vivo relevance of Mrp2-mediated biliary excretion of the Amanita mushroom toxin demethyl-phalloin. Biochim Biophys Acta 1768:2070-2077.
78. Ghosal A, Satoh H, Thomas PE, et al. (1996). Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24: 940-947.
79. Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
80. Gillette JR. (1963). Metabolism of drugs and other foreign compounds by enzymatic mechanisms. Prog Drug Res 6:11-73.
81. Glaeser H. (2011). Importance of P-glycoprotein for drug-drug interactions. Handb Exp Pharmacol 201:285-297.
82. Gomez DY, Wacher VJ, Tomlanovich SJ, et al. (1995). The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19.
83. Gong S, Lu X, Xu Y, et al. (2002). Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp Hematol 30:1162-1169.
84. Gradhand U, Kim RB. (2008). Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev 40:317-354.
85. Gradhand U, Lang T, Schaeffeler E, et al. (2008). Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J 8:42-52.
86. Gramer I, Leidolf R, Döring B, et al. (2011). Breed distribution of the nt230(del4) MDR1 mutation in dogs. Vet J 189:67-71.
87. +-dependent taurocholate cotransporting polypeptide (NTCP). Eur J Pharm Sci 44:487-496.
88. Gründemann D, Gorboulev V, Gambaryan S, et al. (1994). Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372:549-552.
89. Gründemann D, Harlfinger S, Golz S, et al. (2005). Discovery of the ergothioneine transporter. Proc Natl Acad Sci USA 102:5256-5261.
90. Guengerich FP, Shimada T. (1993). Human cytochrome P450 enzymes and chemical carcinogenesis. In: Jeffrey EH, ed. Human Drug Metabolism: From Molecular Biology to Man. Boca Raton: CRC Press, 5-12.
91. Guo Y, Kotova E, Chen ZS, et al. (2003). MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2, 3-dideoxycytidine and 9-(2-phosphonylmethoxyethyl)adenine. J Biol Chem 278:29509-29514.
92. Hagenbuch B, Meier PJ. (2004). Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653-665.
93. Hagenbuch B. (2007). Cellular entry of thyroid hormones by organic anion transporting polypeptides. Best Pract Res Clin Endocrinol Metab 21:209-221.
94. Hagenbuch B, Stieger B. (2013). The SLCO (former SLC21) superfam-ily of transporters. Mol Aspects Med 34:396-412.
95. Hayer-Zillgen M, Brüss M, Bönisch H. (2002). Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 136:829-836.
96. Hediger MA, Romero MF, Peng JB, et al. (2004). The ABCs of solute carriers: Physiological, pathological and therapeutic implications of human membrane transport proteins. Pflugers Arch 447: 465-468.
97. Hediger MA, Clemencon B, Burrier RE, Bruford EA. (2013). The ABCs of membrane transporters in health and disease (SLC series): Introduction. Mol Aspects Med 34:95-107.
98. Higgins CF. (1992). ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8:67-113.
99. Higgins CF, Callaghan R, Linton KJ, et al. (1997). Structure of the multidrug resistance P-glycoprotein. Semin Cancer Biol 8:135-142.
100. Higgins MK, Bokma E, Koronakis E, et al. (2004). Structure of the periplasmic component of a bacterial drug efflux pump. Proc Natl Acad Sci USA 101:9994-9999.
101. Hirano M, Maeda K, Hayashi H, et al. (2005). Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther 314:876-882.
102. Hofmann AF. (2009). The enterohepatic circulation of bile acids in mammals: Form and functions. Front Biosci 14:2584-2598.
103. Hogben CA, Tocco DJ, Brodie BB, Schanker LS. (1959). On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther 125:275-282.
104. Hooijberg JH, Broxterman HJ, Kool M, et al. (1999). Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532-2535.
105. Hopper-Borge EA, Churchill T, Paulose C, et al. (2011). Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice. Cancer Res 71:3649-3657.
106. Horio M, Gottesman MM, Pastan I. (1988). ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 85:3580-3584.
107. Hosoyamada M, Sekine T, Kanai Y, Endou H. (1999). Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol 276:F122-F128.
108. Huang Y. (2007). Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 26:183-201.
109. Huls M, Brown CD, Windass AS, et al. (2008). The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 73:220-225.
110. Ieiri I, Takane H, Otsubo K. (2004). The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 43: 553-576.
111. Ishikawa T. (1992). The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci 17:463-468.
112. Ishikawa T, Tsuji A, Inui K, et al. (2004). The genetic polymorphism of drug transporters: Functional analysis approaches. Pharmacogenomics 5:67-99.
113. Ishikawa T, Sakurai A, Hirano H, et al. (2010). Emerging new technologies in pharmacogenomics: rapid SNP detection, molecular dynamic simulation, and QSAR analysis methods to validate clinically important genetic variants of human ABC Transporter ABCB1 (P-gp/MDR1). Pharmacol Ther 126:69-81.
114. Janke D, Mehralivand S, Strand D, et al. (2008). 6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Hum Mutat 29:659-669.
115. Jansen PL, Peters WH, Lamers WH. (1985). Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 5:573-579.
116. Jedlitschky G, Leier I, Buchholz U, et al. (1997). ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem J 327: 305-310.
117. Jedlitschky G, Hoffmann U, Kroemer HK. (2006). Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol 2:351-366.
118. Jemnitz K, Heredi-Szabo K, Janossy J, et al. (2010). ABCC2/Abcc2: A multispecific transporter with dominant excretory functions. Drug Metab Rev 42:402-436.
119. Johnson BM, Charman WN, Porter CJ. (2001). The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil. J Pharm Pharmacol 53:1611-1619.
120. Jonker JW, Merino G, Musters S, et al. (2005). The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11:127-129.
121. Juliano RL, Ling V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
122. Jumpertz T, Holland IB, Schmitt L. (2009). ABC transporters: A smart example of molecular machineries. In: Ponte-Sucre A, ed. ABC Transporters in Microorganisms. Norfolk, UK: Caister Academic Press, 1-35.
123. Kamisako T, Leier I, Cui Y, et al. (1999). Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multi-drug resistance protein 2. Hepatology 30:485-490.
124. Katragadda S, Budda B, Anand BS, Mitra AK. (2005). Role of efflux pumps and metabolising enzymes in drug delivery. Expert Opin Drug Deliv 2:683-705.
125. Keppler D. (2011). Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol 201:299-323.
126. Kim RB, Fromm MF, Wandel C, et al. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
127. Kim RB, Wandel C, Leake B, et al. (1999). Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16:408-414.
128. Kimura Y, Morita SY, Matsuo M, Ueda K. (2007). Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci 98:1303-1310.
129. Klaassen CD, Aleksunes LM. (2010). Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62: 1-96.
130. Klucken J, Büchler C, Orsó E, et al. (2000). ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci USA 97: 817-822.
131. Koepsell H. (2004). Polyspecific organic cation transporters: Their functions and interactions with drugs. Trends Pharmacol Sci 25: 375-381.
132. Koepsell H, Lips K, Volk C. (2007). Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharma-ceutical implications. Pharm Res 24:1227-1251.
133. Koepsell H. (2013). The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med 34:413-435.
134. Koizumi A, Nozaki J, Ohura T, et al. (1999). Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency. Hum Mol Genet 8:2247-2254.
135. Kontaxi M, Eckardt U, Hagenbuch B, et al. (1996). Uptake of the mycotoxin ochratoxin A in liver cells occurs via the cloned organic anion transporting polypeptide. J Pharmacol Exp Ther 279: 1507-1513.
136. Kotyk A. (1961). Symposium on membrane transport and metabolism. Folia Microbiol 6:141-143.
137. König J, Nies AT, Cui Y, et al. (1999). Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461:377-394.
138. König J. (2011). Uptake transporters of the human OATP family: Molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms. Handb Exp Pharmacol 201:1-28.
139. König J, Müller F, Fromm MF. (2013). Transporters and drug-drug interactions: Important determinants of drug disposition and effects. Pharmacol Rev 65:944-966.
140. Kraft ME, Glaeser H, Mandery K, et al. (2010). The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci 51:2504-2511.
141. Kruh GD, Belinsky MG. (2003). The MRP family of drug efflux pumps. Oncogene 22:7537-7552.
142. Kruijtzer CM, Beijnen JH, Rosing H, et al. (2002). Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943-2950.
143. Kullak-Ublick GA, Stieger B, Meier PJ. (2004). Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126:322-342.
144. Kuppens IE, Witteveen EO, Jewell RC, et al. (2007). A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res 13:3276-3285.
145. Lai Y, Sampson KE, Balogh LM, et al. (2010). Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther 334:936-944.
146. Lai Y, Varma M, Feng B, et al. (2012). Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability- considerations for drug development. Expert Opin Drug Metab Toxicol 8:723-743.
147. Lam JL, Okochi H, Huang Y, Benet LZ. (2006). In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos 34:1336-1344.
148. Lamhonwah AM, Skaug J, Scherer SW, Tein I. (2003). A third human carnitine/organic cation transporter (OCTN3) as a candidate for the 5q31 Crohn's disease locus (IBD5). Biochem Biophys Res Commun 301:98-101.
149. Lamhonwah AM, Ackerley CA, Tilups A, et al. (2005). OCTN3 is a mammalian peroxisomal membrane carnitine transporter. Biochem Biophys Res Commun 338:1966-1972.
150. Lau YY, Wu CY, Okochi H, Benet LZ. (2004). Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: Hepatic enzyme-transporter interplay. J Pharmacol Exp Ther 308:1040-1045.
151. Lee WK, Wolff NA, Thévenod F. (2009a). Organic cation transporters: Physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab 10:617-631.
152. Lee WK, Reichold M, Edemir B, et al. (2009b). Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. Am J Physiol Renal Physiol 296:F1504-F1513.
153. LeFevre PG. (1975). The present state of the carrier hypothesis. In: Bronner F, Kleinzeller A, ed. Current Topics in Membranes and Transport. London: Academic Press, 109-215.
154. Leier I, Jedlitschky G, Buchholz U, Keppler D. (1994a). Characterization of the ATP-dependent leukotriene C4 export carrier in mastocytoma cells. Eur J Biochem 220:599-606.
155. Leier I, Jedlitschky G, Buchholz U, et al. (1994b). The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269:27807-27810.
156. Leier I, Hummel-Eisenbeiss J, Cui Y, Keppler D. (2000). ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int 57:1636-1642.
157. Lennernäs H, Abrahamsson B. (2005). The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol 57:273-285.
158. Leuthold S, Hagenbuch B, Mohebbi N, et al. (2009). Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol 296:C570-C582.
159. Li L, Lee TK, Meier PJ, Ballatori N. (1998). Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J Biol Chem 273: 16184-16191.
160. Li L, Meier PJ, Ballatori N. (2000). Oatp2 mediates bidirectional organic solute transport: A role for intracellular glutathione. Mol Pharmacol 58:335-340.
161. Li Y, Lu J, Paxton JW. (2012). The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phytochemicals and their interactions with xenobiotics. Curr Drug Metab 13:624-639.
162. Litman T, Brangi M, Hudson E, et al. (2000). The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113 (Pt 11):2011-2021.
163. Lowth BR, Kirstein-Miles J, Saiyed T, et al. (2012). Substrate recognition and processing by a Walker B mutant of the human mitochondrial AAA+ protein CLPX. J Struct Biol 179:193-201.
164. Löbenberg R, Amidon GL. (2000). Modern bioavailability, bioequiva-lence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 50:3-12.
165. Löscher W, Luna-Tortos C, Römermann K, Fedrowitz M. (2011). Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr Pharm Des 17:2808-2828.
166. Luo G, Cunningham M, Kim S, et al. (2002). CYP3A4 induction by drugs: Correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795-804.
167. Machavaram KK, Gundu J, Yamsani MR. (2006). Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: A possible role of P-glycoprotein. Drug Metab Drug Interact 22:47-65.
168. Mack JT, Beljanski V, Tew KD, Townsend DM. (2006). The ATP-binding cassette transporter ABCA2 as a mediator of intracellular trafficking. Biomed Pharmacother 60:587-592.
169. Mack JT, Townsend DM, Beljanski V, Tew KD. (2007). The ABCA2 transporter: Intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds. Curr Drug Metab 8:47-57.
170. Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N. (2007). Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol 293:G271-G278.
171. Maliepaard M, Scheffer GL, Faneyte IF, et al. (2001). Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
172. Mandery K, Bujok K, Schmidt I, et al. (2010). Influence of cyclooxygenase inhibitors on the function of the prostaglandin transporter organic anion-transporting polypeptide 2A1 expressed in human gastroduodenal mucosa. J Pharmacol Exp Ther 332: 345-351.
173. Mao Q, Unadkat JD. (2005). Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7:E118-E133.
174. Marie JP, Zhou DC, Gurbuxani S, et al. (1996). MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer 32A:1034-1038.
175. Martin C, Berridge G, Higgins CF, et al. (2000). Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624-632.
176. Martinez M, Modric S, Sharkey M, et al. (2008). The pharmacogenomics of P-glycoprotein and its role in veterinary medicine. J Vet Pharmacol Ther 31:285-300.
177. Marzolini C, Paus E, Buclin T, Kim RB. (2004). Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33.
178. +/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17:2127-2135.
179. Matsushima S, Maeda K, Inoue K, et al. (2009). The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 37:555-559.
180. Mealey KL, Bentjen SA, Gay JM, Cantor GH. (2001). Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene.
181. Mealey KL. (2008). Canine ABCB1 and macrocyclic lactones: Heartworm prevention and pharmacogenetics. Vet Parasitol 158: 215-222.
182. Meier-Abt F, Faulstich H, Hagenbuch B. (2004). Identification of phalloidin uptake systems of rat and human liver. Biochim Biophys Acta 1664:64-69.
183. Meier Y, Pauli-Magnus C, Zanger UM, et al. (2006). Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44:62-74.
184. Meyer zu Schwabedissen HE, Kroemer HK. (2011). In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol 201:325-371.
185. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, et al. (2010) Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 298: F997-F1005.
186. Mikami T, Nozaki Y, Tagaya O, et al. (1986). The character of a new mutant in rats with hyperbilirubinuria syndrome. Cong Anom 26: 250-251.
187. Mikkaichi T, Suzuki T, Onogawa T, et al. (2004). Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci USA 101:3569-3574.
188. Ming X, Knight BM, Thakker DR. (2011). Vectorial transport of fexofenadine across Caco-2 cells: Involvement of apical uptake and basolateral efflux transporters. Mol Pharm 8:1677-1686.
189. Miyake K, Mickley L, Litman T, et al. (1999). Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. Cancer Res 59:8-13.
190. Mo W, Zhang JT. (2012). Human ABCG2: Structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 3:1-27.
191. Morgan ET, Goralski KB, Piquette-Miller M, et al. (2008). Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205-216.
192. Mori K, Ogawa Y, Ebihara K, et al. (1997). Kidney-specific expression of a novel mouse organic cation transporter-like protein. FEBS Lett 417:371-374.
193. Motohashi H, Inui K. (2013). Multidrug and toxin extrusion family SLC47: Physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. Mol Aspects Med 34:661-668.
194. Mouly S, Paine MF. (2003). P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 20:1595-1599.
195. Muntané J. (2009). Regulation of drug metabolism and transporters. Curr Drug Metab 10:932-945.
196. Müller J, Lips KS, Metzner L, et al. (2005). Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 70:1851-1860.
197. Müller M, Roelofsen H, Jansen PL. (1996). Secretion of organic anions by hepatocytes: Involvement of homologues of the multidrug resistance protein. Semin Liver Dis 16:211-220.
198. Neuvonen PJ. (2010). Drug interactions with HMG-CoA reductase inhibitors (statins): The importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 11:323-332.
199. Ni Z, Mao Q. (2011). ATP-binding cassette efflux transporters in human placenta. Curr Pharm Biotechnol 12:674-685.
200. Niemi M, Arnold KA, Backman JT, et al. (2006). Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genom 16:801-808.
201. Niemi M, Pasanen MK, Neuvonen PJ. (2011). Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181.
202. Nies AT, Jedlitschky G, König J, et al. (2004). Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 129: 349-360.
203. Nies AT, Keppler D. (2007). The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 453:643-659.
204. Nies AT, Schwab M, Keppler D. (2008). Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol 4:545-568.
205. Nies AT, Koepsell H, Damme K, Schwab M. (2011). Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 201: 105-167.
206. Nobili S, Landini I, Mazzei T, Mini E. (2012). Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev 32:1220-1262.
207. Obaidat A, Roth M, Hagenbuch B. (2012). The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 52:135-151.
208. Oswald S, Westrup S, Grube M, et al. (2006). Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. J Pharmacol Exp Ther 318:1293-1299.
209. Otsuka M, MatsumotoT, Morimoto R, et al. (2005). A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 102:17923-17928.
210. Oude Elferink RP, Bakker CT, Roelofsen H, et al. (1993). Accumulation of organic anion in intracellular vesicles of cultured rat hepatocytes is mediated by the canalicular multispecific organic anion transporter. Hepatology 17:434-444.
211. Pal D, Mitra AK. (2006). MDR-and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 1:323-339.
212. Patel NH, Rothenberg ML. (1994). Multidrug resistance in cancer chemotherapy. Invest New Drugs 12:1-13.
213. Paul AJ, Tranquilli WJ, Seward RL, et al. (1987). Clinical observations in collies given ivermectin orally. Am J Vet Res 48:684-685.
214. Paulusma CC, Bosma PJ, Zaman GJ, et al. (1996). Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271:1126-1128.
215. Paulusma CC, Kool M, Bosma PJ, et al. (1997). A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25:1539-1542.
216. Petzinger E, Ziegler K, Frimmer M. (1987). Occurence of a multispecific transporter for the hepatocellular accumulation of bile acids and various cyclopeptides. In: Paumgartner G, Stiehl A, Gerok W, ed. Bile Acids and the Liver. Lancaster: MTP-Press, 111-124.
217. Petzinger E, Blumrich M, Brühl B, et al. (1996). What we have learned about bumetanide and the concept of multispecific bile acid/drug transporters from the liver. J Hepatol 24:42-46.
218. Petzinger E, Geyer J. (2006). Drug transporters in pharmacokinetics. Naunyn Schmiedebergs Arch Pharmacol 372:465-475.
219. Poirier A, Funk C, Lave T, Noe J. (2007). New strategies to address drug-drug interactions involving OATPs. Curr Opin Drug Discov Devel 10:74-83.
220. Poller B, Drewe J, Krahenbuhl S, et al. (2010). Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol 30: 63-70.
221. Ponte-Sucre A. (2009). ABC Transporters in Microorganisms. Norfolk: Caister Academic Press.
222. Prasad B, Evers R, Gupta A, et al. (2014). Interindividual variability in hepatic oatps and P-glycoprotein (ABCB1) protein expression: Quantification by LC-MS/MS and influence of genotype, age and sex. Drug Metab Dispos 42:78-88.
223. Pulliam JD, Seward RL, Henry RT, Steinberg SA. (1985). Investigating ivermectin toxicity in Collies. Vet Med 80:33-40.
224. Ren Q, Paulsen IT. (2005). Comparative analyses of fundamental differences in membrane transport capabilities in prokaryotes and eukaryotes. PLoS Comput Biol 1:e27.
225. Rinaldo P, Stanley CA, Hsu BY, et al. (1997). Sudden neonatal death in carnitine transporter deficiency. J Pediatr 131:304-305.
226. Ringpfeil F, Lebwohl MG, Christiano AM, Uitto J. (2000). Pseudoxanthoma elasticum: Mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci USA 97:6001-6006.
227. Riordan JR, Deuchars K, Kartner N, et al. (1985). Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316:817-819.
228. Ritz U, Seliger B. (2001). The transporter associated with antigen processing (TAP): Structural integrity, expression, function, and its clinical relevance. Mol Med 7:149-158.
229. Rizwan AN, Burckhardt G. (2007). Organic anion transporters of the SLC22 family: Biopharmaceutical, physiological, and pathological roles. Pharm Res 24:450-470.
230. Robey RW, Massey PR, Amiri-Kordestani L, Bates SE. (2010). ABC transporters: Unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem 10:625-633.
231. Roninson IB, Chin JE, Choi KG, et al. (1986). Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83:4538-4542.
232. Rosenberg MF, Kamis AB, Callaghan R, et al. (2003). Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 278: 8294-8299.
233. Roth M, Obaidat A, Hagenbuch B. (2012). OATPs, OATs and OCTs: The organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165:1260-1287.
234. Roulet A, Puel O, Gesta S, et al. (2003). MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol 460:85-91.
235. Rubin LJ. (2012). Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci 91:517-521.
236. Rubio-Aliaga I, Daniel H. (2008). Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica 38: 1022-1042.
237. Ryu S, Kawabe T, Nada S, Yamaguchi A. (2000). Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2. J Biol Chem 275: 39617-39624.
238. Saad AH, DePestel DD, Carver PL. (2006). Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 26: 1730-1744.
239. Saier Jr MH, Tran CV, Barabote RD. (2006). TCDB: The Transporter Classification Database for membrane transport protein analyses and information. Nucleic Acids Res 34:D181-D186.
240. Saier Jr MH, Yen MR, Noto K, et al. (2009). The Transporter Classification Database: recent advances. Nucleic Acids Res 37: D274-D278.
241. Salama NN, Kelly EJ, Bui T, Ho RJ. (2005). The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice. J Pharm Sci 94: 1216-1225.
242. Sandusky GE, Mintze KS, Pratt SE, Dantzig AH. (2002). Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41: 65-74.
243. Satlin LM, Amin V, Wolkoff AW. (1997). Organic anion transporting polypeptide mediates organic anion/HCO^ exchange. J Biol Chem 272:26340-26345.
244. Schinkel AH, Smit JJ, van Tellingen O, et al. (1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
245. Schinkel AH, Wagenaar E, van Deemter L, et al. (1995). Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
246. Scholz C, Tampe R. (2005). The intracellular antigen transport machinery TAP in adaptive immunity and virus escape mechanisms. J Bioenerg Biomembr 37:509-515.
247. Schuster VL. (2002). Prostaglandin transport. Prostaglandins Other Lipid Mediat 68-69:633-647.
248. Sekine T, Watanabe N, HosoyamadaM, et al. (1997). Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 272:18526-18529.
249. Seward DJ, Koh AS, Boyer JL, Ballatori N. (2003). Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem 278:27473-27482.
250. Seward RL. (1983). Reactions in dogs given ivermectin. J Am Vet Med Assoc 183:493.
251. Shapiro AB, Fox K, Lam P, Ling V. (1999). Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 259:841-850.
252. Shitara Y, Sugiyama Y (2006). Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105.
253. Siegsmund MJ, Cardarelli C, Aksentijevich I, et al. (1994). Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 151:485-491.
254. Simon C, Stieger B, Kullak-Ublick GA, et al. (2007). Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand 115: 232-242.
255. Smeets PH, Van Aubel RA, Wouterse AC, et al. (2004). Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol 15:2828-2835.
256. Smith AJ, van Helfoort HA, van Meer MG, et al. (2000). MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 275:23530-23539.
257. Smith DE, Clemencon B, Hediger MA. (2013). Proton-coupled oligopeptide transporter family SLC15: Physiological, pharmacological and pathological implications. Mol Aspects Med 34:323-336.
258. Smith JN, Williams RT (1949a). Studies in detoxication. 22. The metabolism of phenacetin (p-ethoxyacetanilide) in the rabbit and a further observation on acetanilide metabolism. Biochem J 44: 239-242.
259. Smith JN, Williams RT. (1949b). Studies in detoxication. 23. The fate of aniline in the rabbit. Biochem J 44:242-250.
260. Smith JN, Williams RT. (1949c). Studies in detoxication. 24. The metabolism of p-phenetidine (p-ethoxyaniline) with some observations on the anisidines (methoxyanilines). Biochem J 44:250-255.
261. Stieger B, Meier PJ. (2011). Pharmacogenetics of drug transporters in the enterohepatic circulation. Pharmacogenomics 12:611-631.
262. Summerfield SG, Stevens AJ, Cutler L, et al. (2006). Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther 316:1282-1290.
263. Suzuki H, Sugiyama Y. (2000). Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 12:3-12.
264. Suzuki H, Sugiyama Y. (2002). Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): Its impact on drug disposition. Adv Drug Deliv Rev 54:1311-1331.
265. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. (2003). ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278:22644-22649.
266. Szakács G, Paterson JK, Ludwig JA, et al. (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234.
267. Tamai I, Yabuuchi H, Nezu J, et al. (1997). Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett 419:107-111.
268. Tamai I, Ohashi R, Nezu J, et al. (1998). Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273:20378-20382.
269. Tamai I, Ohashi R, Nezu JI, et al. (2000). Molecular and functional characterization of organic cation/carnitine transporter family in mice. J Biol Chem 275:40064-40072.
270. Tamai I. (2013). Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). Biopharm Drug Dispos 34:29-44.
271. Taniguchi K, Wada M, Kohno K, et al. (1996). A human canalicular multispecific organic anion transporter (cMOAT) gene is over-expressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124-4129.
272. Tanihara Y, Masuda S, Sato T, et al. (2007). Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 74:359-371.
273. Thiebaut F, Tsuruo T, Hamada H, et al. (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
274. Tian X, Zamek-Gliszczynski MJ, Li J, et al. (2008). Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos 36:61-64.
275. Tirona RG. (2011). Molecular mechanisms of drug transporter regulation. Handb Exp Pharmacol 201:373-402.
276. Tranquilli WJ, Paul AJ, Seward RL. (1989). Ivermectin plasma concentrations in collies sensitive to ivermectin-induced toxicosis. Am J Vet Res 50:769-770.
277. Tzvetkov MV, Saadatmand AR, Lötsch J, et al. (2011). Genetically polymorphic OCT1: Another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther 90:143-150.
278. Tzvetkov MV, Saadatmand AR, Bokelmann K, et al. (2012). Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J 12:22-29.
279. Ueda K, Clark DP, Chen CJ, et al. (1987a). The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 262:505-508.
280. Ueda K, Cardarelli C, Gottesman MM, Pastan I. (1987b). Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84: 3004-3008.
281. van de Kerkhof EG, de Graaf IA, Ungell AL, Groothuis GM. (2008). Induction of metabolism and transport in human intestine: Validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro. Drug Metab Dispos 36:604-613.
282. van Herwaarden AE, Schinkel AH. (2006). The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci 27:10-16.
283. van Herwaarden AE, Wagenaar E, Karnekamp B, et al. (2006). Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 27:123-130.
284. van Waterschoot RA, Lagas JS, Wagenaar E, et al. (2009). Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 69:8996-9002.
285. van Waterschoot RA, Schinkel AH. (2011). A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: Recent insights from knockout and transgenic mice. Pharmacol Rev 63: 390-410.
286. Vähäkangas K, Myllynen P. (2009). Drug transporters in the human blood-placental barrier. Br J Pharmacol 158:665-678.
287. Venitz J, Zack J, Gillies H, et al. (2012). Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol 52:1784-1805.
288. Vlaming ML, Mohrmann K, Wagenaar E, et al. (2006). Carcinogen and anticancer drug transport by Mrp2 in vivo: Studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318:319-327.
289. Wacher VJ, Wu CY, Benet LZ. (1995). Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
290. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. (1998). Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322-1330.
291. Wacher VJ, Salphati L, Benet LZ. (2001). Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 46:89-102.
292. Walker JE, Saraste M, Runswick MJ, Gay NJ. (1982). Distantly related sequences in the alpha-and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1:945-951.
293. Wandel C, Kim RB, Kajiji S, et al. (1999). P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies. Cancer Res 59:3944-3948.
294. Wang EJ, Lew K, Casciano CN, et al. (2002). Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 46:160-165.
295. Wang L, Giannoudis A, Lane S, et al. (2008a). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83:258-264.
296. Wang Y, Ye J, Ganapathy V, Longo N. (1999). Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc Natl Acad Sci USA 96:2356-2360.
297. Wang ZJ, Yin OQ, Tomlinson B, Chow MS. (2008b). OCT2 polymorphisms and in-vivo renal functional consequence: Studies with metformin and cimetidine. Pharmacogenet Genomics 18:637-645.
298. Warren MS, Zerangue N, Woodford K, et al. (2009). Comparative gene expression profiles of ABC transporters in brain microvessel endo-thelial cells and brain in five species including human. Pharmacol Res 59:404-413.
299. Watkins PB. (1997). The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161-170.
300. Williams RT (1959). Detoxication Mechanisms. The Metabolism and Detoxification of Drugs, Toxic Substances and Other Organic Compounds. 2nd edition. London: Chapman and Hall Ltd.
301. Wittner M, Di SA, Wangemann P, Greger R. (1991). How do loop diuretics act? Drugs 41:1-13.
302. Wu CY, Benet LZ. (2005). Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
303. Wulf GG, Modlich S, Inagaki N, et al. (2004). ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. Hematologica 89:1395-7.
304. Xu C, Li CY, Kong AN. (2005). Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 28:249-268.
305. Xu J, Liu Y, Yang Y, et al. (2004). Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 279: 19781-19789.
306. Xuan W, Lamhonwah AM, Librach C, et al. (2003). Characterization of organic cation/carnitine transporter family in human sperm. Biochem Biophys Res Commun 306:121-128.
307. Yamazaki K, Mikami T, Hosokawa S, et al. (1995). A new mutant rat with hyperbilirubinuria (hyb). J Hered 86:314-317.
308. Yasuda K, Lan LB, Sanglard D, et al. (2002). Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 303: 323-332.
309. Yonezawa A, Inui K. (2011). Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmaco-dynamics/ toxicodynamics and pharmacogenomics. Br J Pharmacol 164:1817-1825.
310. Young JD, Yao SY, Baldwin JM, et al. (2013). The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol Aspects Med 34:529-547.
311. Zamek-Gliszczynski MJ, Hoffmaster KA, Tweedie DJ, et al. (2012). Highlights from the International Transporter Consortium second workshop. Clin Pharmacol Ther 92:553-556.
312. Zhang L, Zhang YD, Strong JM, et al. (2008). A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709-724.
313. Zhang Y, Benet LZ. (2001). The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159-168.
314. Zhou SF, Lai X. (2008). An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr Drug Metab 9: 394-409.
315. Zhou SF. (2008). Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38: 802-832.
316. Ziegler K, Frimmer M, Kessler H, et al. (1985). Modified somatostatins as inhibitors of a multispecific transport system for bile acids and phallotoxins in isolated hepatocytes. Biochim Biophys Acta 845: 86-93.
317. +-dependent taurocholate uptake in basolateral (sinusoidal) rat liver plasma membrane vesicles. J Pharmacol Exp Ther 250: 301-308.
318. Zimniak P. (1993). Dubin-Johnson and Rotor syndromes: molecular basis and pathogenesis. Semin Liver Dis 13:248-260.
319. Zimniak P, Awasthi S, Awasthi YC. (1993). Phase III detoxification system. Trends Biochem Sci 18:164-166.
320. Zolk O, Fromm MF. (2011). Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. Clin Pharmacol Ther 89:798-805.